Company Overview and News
TORONTO, June 06, 2018 (GLOBE NEWSWIRE) -- Firan Technology Group Corporation (TSX:FTG) announced today that it has been awarded new Long Term Agreements from Rockwell Collins for the supply of Printed Wiring Boards (PWBs).
FTG FTGFF COL
TORONTO, April 18, 2018 (GLOBE NEWSWIRE) -- Firan Technology Group Corporation (TSX:FTG) today announced the results of its annual general meeting of shareholders (“AGM”), held in Toronto, Ontario on April 17, 2018. The Corporation is pleased to report that each of the director nominees listed in its management information circular dated March 5, 2018 were elected as directors of FTG. The directors have been elected to serve until the close of the next annual meeting of shareholders.
TORONTO, April 04, 2018 (GLOBE NEWSWIRE) -- Firan Technology Group Corporation (TSX:FTG) will release the Q1 2018 financial results after close of trading on Wednesday, April 11, 2018.
TORONTO, March 26, 2018 (GLOBE NEWSWIRE) -- Firan Technology Group Corporation (TSX:FTG), through its FTG Aerospace Toronto division, announced today that they have signed an amendment, valued at over $4 million USD to their long-term agreement with SAVIC for the design, development, certification support and long-term production for the Entry into Service (EIS) configuration of various Display Suite Control Panel Assemblies, deployed on the new COMAC C919 Aircraft.
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
Silicon Investor Message Boards
This table lists all message boards related to TSX:FTG / Firan Technology Group C on message board site Silicon Investor.
|OTC:BB FTGX: Fibernet Telecom Group||FTG_FARMSTEAD-AMEX|
|FARMSTEAD TELEPHONE (FTG)|